EIF2AK3 and cancer: Potent small-molecule PERK inhibitors were generated recently and tested in preclinical mouse studies on cancer and prion disease.13, 14, 15 However, while an extensive effort was made to elucidate the downstream signaling of PERK over the past years, much less is known about regulatory components upstream of PERK.